![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Persistence of NS5A Drug Resistance Mutations Following 3 Days of GS-5885 Monotherapy in Genotype-1 HCV Patients is Dependent on the HCV Subtype and Specific Mutation
|
|
|
Reported by Jules Levin
EASL 2012
Apr 18-22 Barcelona Spain
KA Wong1, A Worth1, DM Brainard1, E Lawitz2, MD Miller1, H Mo1
1Gilead Sciences, Inc., Foster City, CA, USA, 2Alamo Medical Research, San Antonio, TX, USA
![EASL1.gif](../images/042512/042512-1/EASL1.gif)
![EASL2.gif](../images/042512/042512-1/EASL2.gif)
![EASL3.gif](../images/042512/042512-1/EASL3.gif)
![EASL4.gif](../images/042512/042512-1/EASL4.gif)
![EASL5.gif](../images/042512/042512-1/EASL5.gif)
![EASL6.gif](../images/042512/042512-1/EASL6.gif)
![EASL7.gif](../images/042512/042512-1/EASL7.gif)
![EASL8.gif](../images/042512/042512-1/EASL8.gif)
![EASL9.gif](../images/042512/042512-1/EASL9.gif)
![EASL10.gif](../images/042512/042512-1/EASL10.gif)
![EASL11.gif](../images/042512/042512-1/EASL11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|